Manufacturing and banking canine adipose-derived mesenchymal stem cells for veterinary clinical application

Abstract

Background Mesenchymal stem cells (MSCs) have generated a great amount of interest in recent years as a novel therapeutic application for improving the quality of pet life and helping them free from painful conditions and diseases. It has now become critical to address the challenges related to the safety and efficacy of MSCs expanded in vitro. In this study, we establish a standardized process for manufacture of canine adipose-derived MSCs (AD-MSCs), including tissue sourcing, cell isolation and culture, cryopreservation, thawing and expansion, quality control and testing, and evaluate the safety and efficacy of those cells for clinical applications. Results After expansion, the viability of AD-MSCs manufactured under our standardized process was above 90 %. Expression of surface markers and differentiation potential was consistent with ISCT standards. Sterility, mycoplasma, and endotoxin tests were consistently negative. AD-MSCs presented normal karyotype, and did not form in vivo tumors. No adverse events were noted in the case treated with intravenously AD-MSCs. Conclusions Herein we demonstrated the establishment of a feasible bioprocess for manufacturing and banking canine AD-MSCs for veterinary clinical use.

Plant-derived leaf vein scaffolds for the sustainable production of dog cell-cultured meat

“…The isolation and culture of ASCs have been effectively established through our previous successful method( Luo et al, 2021 ). Adipose tissue was digested with type I collagenase to obtain nucleated cells and seeded in cell culture dishes.…”

“…Adipose-derived stromal cells (ASCs) were isolated and culture as previously described( Luo, Li, Chen, Wang, & Chen, 2021 ; Zhang et al, 2018 ). Briefly, adipose tissues were minced, digested with collagenase type I at 37 °C for 1–2 h, filtered through a 70 μm cell strainer, and then cultured with adipose mesenchymal stem cell complete culture medium (Oricell, Cyagen Biosciences, China) at 37 °C with 5% CO2.…”

Evaluation of canine adipose-derived mesenchymal stem cells for neurological functional recovery in a rat model of traumatic brain injury

“…Method for isolation, culture and dentification of canine AD-MSCs were according to our previous study [ 30 ]. Briefly, Approximately 2–6 × 10 6 AD-MSCs were obtained from canine adipose tissue ( n = 12, range 2–5 g), digested by type I collagenase and seeded into 100 mm cell -culture dishes.…”

Exploring the Tumor-Associated Risk of Mesenchymal Stem Cell Therapy in Veterinary Medicine

“…Several studies have investigated stem cell tumorigenicity in immunodeficient mice. In NOD/SCID mice, canine adipose-derived stem cells were subcutaneously injected, and after a 40 d observation period, no tumor formation was observed in contrast to the positive control group, which received HeLa cells [22]. Similarly, in nude mice, various doses of human adipose-derived MSCs were injected and monitored for 13 weeks after intravenous injection and 26 weeks after subcutaneous injection.…”